Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Abstract

The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.

SPOCD1 regulated by miR-133a-3p promotes hepatocellular carcinoma invasion and metastasis

“…However, expression levels of PTX3 vary among HCC cell lines, 26 and it is considered to have no diagnostic value in HCC patients because its expression is not related to the TNM classification of HCC. 27 The results of the current UALCAN analysis also found no relationship between PTX3 expression level and tumor grade or survival prognosis in HCC patients (data not shown). This suggests that SPOCD1 may promote HCC tumorigenesis through a PTX3-independent pathway.…”

Increased Serum Pentraxin 3 Levels are Associated with Poor Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma

“…[18][19][20]34 It should be noted that there is a study showing that PTX3 is not related to disease severity in cirrhosis and HCC patients. 35 However, this study included relatively small number of cirrhosis (n=35) and HCC (n=31) patients. 35 More other studies confirmed the potential of PTX3 as a biomarker in evaluating the disease severity and prognosis of cirrhosis 36 and HCC.…”

“…35 However, this study included relatively small number of cirrhosis (n=35) and HCC (n=31) patients. 35 More other studies confirmed the potential of PTX3 as a biomarker in evaluating the disease severity and prognosis of cirrhosis 36 and HCC. [18][19][20]34 The present study showed that increased serum PTX3 levels were associated with poor prognosis of HBV-related HCC and high PTX3 level was an independent factor associated with a reduced survival time of HCC patients.…”

Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis

“…During TIPS, EDTA plasma was obtained from the hepatic vein (HVP), the portal vein (PVP) and from a peripheral vein (SVP). These blood samples were used in former studies [31][32][33][34][35] Medicine. Analysis of cholesteryl ester and sphingolipid species in our patients with liver cirrhosis has been done before and data were published [36].…”

“…The human PCSK9 DuoSet ELISA was used (R&D Systems; Wiesbaden, Nordenstadt, Germany) as specified by the provider (dilution 1:100). Resistin, galectin-3, IL-6, adiponectin, leptin, chemerin and pentraxin 3 were measured in serum / plasma before [31][32][33][34][35].…”